Synopsis
Preface.- Preclinical Experience with AMD3100 for Mobilization of Hematopoietic Stem and Progenitor Cells.- Molecular Pharmacology of CXCR4 Inhibition.- Combination Strategies for Stem Cell Mobilization Targeting CXCR4 and S1P Receptors.- Should We Stay Or Should We Go Now?
Cell Adhesion and Mobilization Pathways of Hematopoietic Cellls.- Role of the CXCR4/CXCL12 Axis in Hematopoietic Stem Cell Trafficking.- Early Studies of AMD3100/Plerixafor in Healthy Volunteers.- The Current Role of Plerixafor in Stem Cell Mobilization for Hematopoietic Stem Cell Transplantation.- Relevance and Clinical Implications of Tumor Cell Mobilization in Autologous Transplantation of Multiple Myeloma and non Hodgkin's lymphoma.- Plerixafor - Data from the Compassionate Use Program.- Stem Cell Mobilization with Chemomobilization plus Plerixafor in Hard-To-Mobilize Patients - The Experience at Kuopio University Hospital, Finland.- Blood Stem Cell Mobilization in Solid Tumors - Experience with Plerixafor and Alternative Ways of Hematopoietic Stem Cell Mobilization.- Mobilization with Chemotherapy+G-CSF+Plerixafor in Europe- the Italian experience.- Experience with Plerixafor in Poor Mobilizers.- CXCR4 Antagonists.- Application of CXCR4-Inhibitors in Leukemia.- CXCR4 Antagonists for the Treatment of CML.- Targeting CXCR4 in Chronic Lymphocytic Leukemia (CLL): Preclinical Rationale and Early Clinical Experience.- CXCR4-Blockade for Treatment of Breast Cancer.- Molecular Imaging of CXCR4 Receptor Expression in Tumors.- Potential Use of CXCR4 Antagonists to Mobilize Endothelial and Mesenchymal Stem Cells.- Strategies to Enhance Hematopoietic Stem Cell Engraftment Following Transplantation.- Mobilization for Gene Therapy.- Index.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
